November, 2022

article thumbnail

Co-crystallization in drug development ~ Exploring the benefits of co-crystals ~

Drug Discovery Today

Over the last decade, co-crystallization has become an attractive alternative to improve the physiochemical properties of drugs without affecting their pharmacology. As a result of the pharmaceutical benefits co-crystals exhibit, industrial interest is on the rise. Here Dr. Thomas Kendall, application specialist at crystallization and solid-state specialist Technobis Crystallization Systems, gives a perspective on the benefits of co-crystals and explains how they can be screened.

article thumbnail

Anticancer and apoptotic activity in neuroblastoma SK?N?SH using phospholipid extract from bone of Scomberomorus niphonius

Chemical Biology and Drug Design

Scomberomorus niphonius is the fish eaten worldwide. In this study, we extracted phospholipids from these fish bones using an advanced supercritical CO 2 extraction technique and tested them against neuroblastoma and normal (HUVEC) cells. The molecular findings indicate phospholipids have an apoptotic activity in neuroblastoma. Abstract Among various types children's health challenges, neuroblastoma is the most serious solid neoplasm forming outside the cranium.

DNA 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A quiet revolution in the world of proteomics

DrugBaron

Proteomics – examining the panoply of proteins within a complex sample – has been around much longer than the word we use today to describe it. Proteomics the word was coined in around 1997 as a portmanteau coupling the now-ubiquitous “omics” suffix to the word protein. But two decades earlier two-dimensional gel electrophoresis was the cutting-edge technology that first visualised the “complete” catalogue of proteins in a sample, such as a cell lysate or blood sample.

article thumbnail

Talk of the Towne Episode 05: Diversity in research with Allison Kalloo

Antidote

Antidote’s podcast, Talk of the Towne , focuses on the ultimate sweet spot: that special place where science and patients converge. Our host, Dr. Rich Towne, was trained in pharmacy and currently works in Clinical Informatics at Antidote. In each episode, Rich welcomes a new guest from an Antidote partner organization, and takes an in-depth look at a particular area of interest, zeroing in on the story that Antidote's data is telling about how best to connect patients and research.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

From U.S. Air Force Captain to CRO Leader: Karl D. Kendall Shares His Story

Conversations in Drug Development Trends

At Worldwide, we are committed to a cause that extends beyond ourselves. Our mission is to work with passion and purpose every day to improve lives. Our study teams are committed to working collaboratively with our sponsors, united in purpose. Worldwide aims to become an employer of choice?for veterans, military members, and?their families, by creating an?

article thumbnail

Behind the GoodRx-Express Scripts Partnership: How PBMs Profit from Discount Cards in Pharmacy Benefits

Drug Channels

Last week, GoodRx announced that it would become the exclusive prescription discount card provider for the commercial beneficiaries of Cigna’s Express Scripts. Links below. The rise of discount card pricing within pharmacy benefit plans is a positive development. Patients get access to market prices that can be lower than their PBM’s contracted rate.

More Trending

article thumbnail

Sinomenine attenuates lipopolysaccharide?induced inflammation and apoptosis of WI?38 cells by reducing glutathione S?transferase M1 expression

Chemical Biology and Drug Design

Sinomenine protected WI-38 cells against lipopolysaccharide-caused viability reduction, inflammation and apoptosis via downregulating glutathione S-transferase M1 expression. Abstract Pediatric pneumonia is an infectious lung disease with high morbidity and mortality. Sinomenine, an alkaloid extracted from Caulis Sinomenii , exerts anti-inflammatory and anti-apoptotic activities.

Treatment 100
article thumbnail

Which pharmaceutical companies have the most suppository dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most suppository dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suppository dosed drugs…. The post Which pharmaceutical companies have the most suppository dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

The differences between osteoporosis and osteoarthritis

Antidote

Osteoporosis and osteoarthritis (OA) are conditions with different causes and symptoms, but because people are often diagnosed with both, the terms are frequently used interchangeably.

98
article thumbnail

Raters & Therapists: Protecting the validity of your study’s data in a psychedelic trial

Conversations in Drug Development Trends

Psychiatry has long embraced treatment options other than pharmaceuticals. So, it should come as no surprise that as the field explores the use of psychedelics as treatment options for mental illnesses, they are studying the use of psychological therapy alongside them. This is called “psychedelic-assisted psychotherapy” (PAP). But in a clinical trial setting, what role does a therapist play and how do they affect the clinical trial data?

Trials 59
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Cell and Gene Therapy Roundup: What the Road to Success Looks Like

Drug Channels

Today’s guest post comes from Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen. Lung-I discusses advancements in cell and gene therapy and explains how to tackle the challenges facing manufacturers, providers, and patients. Click here to learn about AmerisourceBergen’s Cell and Gene Therapy solutions for biopharma companies, providers, and patients.

article thumbnail

Discovery Park celebrates 10 years and plans to double jobs over the next decade

Drug Discovery Today

The team behind the success of one the country’s largest science and innovation park has announced its plans to grow and double the number of people employed on site as it celebrates a decade of delivering jobs and investment in the South East.

Science 113
article thumbnail

In Silico in Action: A Case Study in Relapsing Remitting Multiple Sclerosis

The Premier Consulting Blog

Computer modeling and simulation of humans, both healthy and with diseases, is a powerful tool. It can augment preclinical and clinical research through mechanistic and predictive investigations that would otherwise be impossible. In recent years, regulatory agencies have begun to accept evidence obtained through modeling and simulation, and in silico clinical trials have emerged as an important approach for virtual testing of pharmacological therapies and medical devices.

Trials 52
article thumbnail

Cream dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for cream dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Cream dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 79
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

What are the types of mitral valve regurgitation?

Antidote

Mitral valve regurgitation, also known as mitral regurgitation, mitral insufficiency, or mitral incompetence, is the most common type of heart valve disease , affecting more than 2% of the population. Though mild mitral valve regurgitation does not usually cause issues, it is a condition that can worsen with time and lead to more severe symptoms. Below, we will be looking at what this condition is, what the common causes are, and some symptoms of mitral valve regurgitation that are helpful to kn

Disease 98
article thumbnail

Applications of Genetically Engineered Organoids and Cell Lines

Crown Bioscience

This post explores applications of genetically engineered organoids and cell lines to expand and accelerate anti-cancer drug discovery and development. We first provide a brief overview of two major methods that are used to develop engineered organoids/cell lines (i.e., lentiviral transduction and PiggyBac), followed by typical workflows for generating these models.

article thumbnail

Preferred Pharmacy Networks in 2023’s Medicare Part D Plans: Cigna, CVS Health, Humana, UnitedHealthcare, WellCare, and More

Drug Channels

Open enrollment is under way for the 2023 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as an established component of Part D benefit design. For 2023: 98% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. 52% of Medicare Advantage prescription drug (MA-PD) plans will have a preferred network.

article thumbnail

Patient-specific cancer tumours replicated in 3D bioprinting advance

Drug Discovery Today

Bowel cancer patients could in future benefit from a new 3D bioprinting technology which would use their own cells to replicate the complex cellular environment of solid tumours in 3D models. The University of Bristol-led advance, published in Biofabrication, would allow clinicians to treat the models, known as spheroids, with chemotherapy drugs and radiation to help them understand an individual patient’s resistance to therapies.

Therapies 113
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Bayesian Adaptive Clinical Trial Designs: INLA vs. MCMC

Cytel

Bayesian methods have continuously played a key role in transforming clinical research in therapeutic areas such as oncology and rare diseases, and in addressing clinical development challenges for COVID-19 drugs, devices, and biologics. From early-phase trials to late-phase development, utilizing Bayesian tools can expedite and/or de-risk trials, even when used to augment a Frequentist framework.

article thumbnail

Which pharmaceutical companies have the most drug patents in Cyprus?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Lung Cancer Awareness Month: Helping patients through research

Antidote

Lung Cancer Awareness Month occurs every November with the purpose of increasing general knowledge of lung cancer and the treatment options available to patients who have been diagnosed. While lung cancer is still a prevalent disease, there have been many advancements in the lung cancer treatment space over the years, and medical research studies are consistently underway to find better solutions for patients.

article thumbnail

Protein Assays | BMG LABTECH

BMG Labtech

What are proteins? Next to carbohydrates, lipids and nucleic acids, proteins are one of the main macromolecule building blocks of life. On a molecular basis, they can be described as complex polymers of amino acids, connected via a peptide bond backbone (fig.1). There are 20 different types of amino acids available as possible residues of individual subunits of a protein.

Science 52
article thumbnail

Innovate4Outcomes: Collaborating to Solve Antimicrobial Resistance

Drug Channels

Today’s guest post comes from Matthew Balogh, Head of Digital Marketing at Melinta Therapeutics. Matt discusses the ongoing global problem of antimicrobial resistance (AMR). He suggests that lessons learned from the COVID-19 pandemic can inform both innovation in AMR therapies and our understanding of AMR. To learn more about the global challenge of AMR and brainstorm solutions, request an invitation to Innovate4Outcomes ®.

article thumbnail

Nerve cell discovery may lead to better treatment for diseases of the nervous system

Drug Discovery Today

A discovery that may improve treatment options for patients with neurodegenerative diseases has been made by scientists at King’s College London and the University of Bath.

Treatment 113
article thumbnail

Regulatory Trends in Cell and Gene Therapies

Advarra

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines. There have been recent signals indicating the Food and Drug Administration (FDA) plans to provide greater support for CGT, addressing key issues continuing to impede their development.

article thumbnail

Which pharmaceutical companies have the most drug patents in Croatia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

The holiday season and mental health: Tips for managing stress and staying healthy

Antidote

While the holiday season can be a time filled with joy and cheer, for many, these are not the only emotions associated with this time of year. In fact, a 2021 survey found that 3 in 5 Americans feel that their mental health is negatively impacted by the holidays.

98
article thumbnail

Open Targets Platform 22.11 has been released!

The Open Targets Blog

The latest release of the Platform — 22.11 — is now available at platform.opentargets.org. Key points In addition to continuous updates from our data providers, we have introduced the following new features: Gene burden data for Parkinson’s disease Updated classifications for clinical trial stop reasons Variant functional consequences, available to browse in the Gene2Phenotype and Orphanet widgets Key stats Metric Count Targets 62,678 Diseases 22,274 Drugs 12,854 Evidence 14

article thumbnail

The Consolidated Drug Channel and Cash-Pay Drugs: My Podcast with a16z's Julie Yoo

Drug Channels

I recently joined Julie Yoo on Bio Eats World , a podcast from legendary venture capital firm Andreessen Horowitz (also known as "a16z"). Julie is a General Partner at Andreessen Horowitz. We chatted about the current state of the U.S. drug channel, the roles and controversies around pharmacy benefit managers (PBMs), GoodRx, Mark Cuban’s cost-plus pharmacy, the 340B Drug Pricing Program, and much more.

article thumbnail

North West chemical manufacturer secures £2.2m to supercharge growth

Drug Discovery Today

Chemical manufacturer LCC has raised £2.2m of investment from a panel of regional investors, to expand its team and continue its global operation from the UK.

113
113
article thumbnail

Biosimilar Clinical Trials and US FDA Guidance

ProRelix Research

Biological products have unlocked the potential for the management of several diseases such as cancers and autoimmune diseases for which treatment with small molecule, chemically synthesized drug molecules remain suboptimal. […]. The post Biosimilar Clinical Trials and US FDA Guidance appeared first on ProRelix Research.

article thumbnail

Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization?

Drug Patent Watch

This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Alzheimer's vs. dementia: An overview for National Alzheimer's Disease Awareness Month

Antidote

While there are many conditions that can cause memory loss , dementia and Alzheimer’s disease are probably two of the most well-known terms associated with cognitive decline. However, while these two terms are often used interchangeably, they actually refer to different kinds of memory loss diseases. In honor of November being National Alzheimer’s Disease Awareness Month , we wanted to take a few moments to address some important considerations when comparing Alzheimer’s and dementia.

Disease 98